BCL2 and gastric cancer: Given that GC is often diagnosed in advanced stages, the evidence of Bcl-2’s early-stage involvement and its role in drug resistance provides a strong rationale for exploring Bcl-2 inhibitors, perhaps in combination therapies, to improve treatment outcomes at all stages of disease.